Skip to main content

Market Overview

Akers Bioscience Reports Signing of European Distribution Deal for PIFA Heparin PF4 Rapid Assay Products

Share:

Akers Biosciences, Inc.
(Nasdaq: AKER) has entered
into its first European distribution agreements since the installment of its
international vice president in August 2014. The Company has entered into
multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products
with Cryopep SARL, covering France, Belgium, the Netherlands and Luxembourg;
and DiaLine AG, covering Switzerland and Lichtenstein.

The Company's PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 are the only US
and EU cleared rapid manual assays that quickly determine if a patient being
treated with the blood thinner heparin may be developing a drug allergy. This
clinical syndrome known as heparin‐induced thrombocytopenia ("HIT") reverses
the heparin's intended therapeutic effect and transforms it into a clotting
agent. Patients suffering HIT are at risk of developing limb- and
life-threatening complications, so the timely test result provided by the
Company's Heparin/PF4 devices is paramount to effective, clinical decision
making. Millions of patients are exposed to heparin around the world each year
and 1% to 5% of those patients receive a HIT diagnosis. The largest at-risk
populations are patients undergoing major cardiac or orthopedic surgical
procedures.

Cryopep (headquartered in Montpellier, France) and DiaLine (headquartered in
Lausen, Switzerland) are both leaders in the field of haemostasis, which
includes coagulation disorders such as HIT. Cryopep's managing director,
Norbert Benattar, has been involved in the sale of haemostasis related
products since 1987, including as a director of marketing and sales for
Diagnostica Stago and Horiba ABX Biogenic; while DiaLine has been distributing
haemostasis related products for over 17 years.

"Cryopep and DiaLine's respective expertise in the coagulation business makes
us confident that we have selected strong partners to launch the PIFA
Heparin/PF4 Rapid Assay products into these European territories," said
Nicolas Daurel, the Company's Vice President Sales and Marketing for Europe,
Middle East and Africa. "I look forward to supporting their marketing
strategies."

"Growing international distribution, particularly of the Company's flagship
PIFA Heparin/PF4 Rapid Assay products, is a core component of Akers
Biosciences' growth strategy," said Raymond F. Akers, Jr. PhD, Co-founder and
Executive Chairman of the Board. "I am delighted to see the first pieces of
the European network established, adding to the already established
distribution channels in the US, China, India, Australia and the Middle East."

 

Related Articles (AKER)

View Comments and Join the Discussion!

Posted-In: News FDA Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com